Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Sarah Goldman-Mazur; Artur Jurczyszyn; Jorge J. Castillo; Anna Waszczuk-Gajda; Norbert Grząśko; Jakub Radocha; Max Bittrich; Klaus Martin Kortüm; Alessandro Gozzetti; Lidia Usnarska-Zubkiewicz; Julio D. Valls; David S. Jayabalan; Ruben Niesvizky; Julia Kelman; Daniel Coriu; Laura Rosiñol; Łukasz Szukalski; Veronica González-Calle; María Victoria Mateos; Krzysztof Jamroziak; Iwona Hus; Irit Avivi; Yael Cohen; Piotr Mazur; Anna Suska; Aimee Chappell; Deepu Madduri; Saurabh Chhabra; Ariel Kleman; Parameswaran Hari; Michel Delforge; Paweł Robak; Massimo Gentile; Izabela Kozłowska; Stuart L. Goldberg; Jacek Czepiel; Monika Długosz-Danecka; Rebecca Silbermann; Adam J. Olszewski; Peter Barth; Gabor Mikala; Chor S. Chim; David H. Vesole

doi:10.1080/10428194.2020.1749605

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Sarah Goldman-Mazur, Artur Jurczyszyn, Jorge J. Castillo, Anna Waszczuk-Gajda, Norbert Grząśko, Jakub Radocha, Max Bittrich, Klaus Martin Kortüm, Alessandro Gozzetti, Lidia Usnarska-Zubkiewicz, Julio D. Valls, David S. Jayabalan, Ruben Niesvizky, Julia Kelman, Daniel Coriu, Laura Rosiñol, Łukasz Szukalski, Veronica González-Calle, María Victoria Mateos, Krzysztof JamroziakIwona Hus, Irit Avivi, Yael Cohen, Piotr Mazur, Anna Suska, Aimee Chappell, Deepu Madduri, Saurabh Chhabra, Ariel Kleman, Parameswaran Hari, Michel Delforge, Paweł Robak, Massimo Gentile, Izabela Kozłowska, Stuart L. Goldberg, Jacek Czepiel, Monika Długosz-Danecka, Rebecca Silbermann, Adam J. Olszewski, Peter Barth, Gabor Mikala, Chor S. Chim, David H. Vesole

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients–223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).

Original language	English (US)
Pages (from-to)	1885-1893
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	61
Issue number	8
DOIs	https://doi.org/10.1080/10428194.2020.1749605
State	Published - Jul 2 2020

Keywords

MAF
Translocation
myeloma
survival
t(14;16)
t(14;20)

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1749605

Cite this

Goldman-Mazur, S., Jurczyszyn, A., Castillo, J. J., Waszczuk-Gajda, A., Grząśko, N., Radocha, J., Bittrich, M., Kortüm, K. M., Gozzetti, A., Usnarska-Zubkiewicz, L., Valls, J. D., Jayabalan, D. S., Niesvizky, R., Kelman, J., Coriu, D., Rosiñol, L., Szukalski, Ł., González-Calle, V., Mateos, M. V., ... Vesole, D. H. (2020). Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 61(8), 1885-1893. https://doi.org/10.1080/10428194.2020.1749605

Goldman-Mazur, S, Jurczyszyn, A, Castillo, JJ, Waszczuk-Gajda, A, Grząśko, N, Radocha, J, Bittrich, M, Kortüm, KM, Gozzetti, A, Usnarska-Zubkiewicz, L, Valls, JD, Jayabalan, DS, Niesvizky, R, Kelman, J, Coriu, D, Rosiñol, L, Szukalski, Ł, González-Calle, V, Mateos, MV, Jamroziak, K, Hus, I, Avivi, I, Cohen, Y, Mazur, P, Suska, A, Chappell, A, Madduri, D, Chhabra, S, Kleman, A, Hari, P, Delforge, M, Robak, P, Gentile, M, Kozłowska, I, Goldberg, SL, Czepiel, J, Długosz-Danecka, M, Silbermann, R, Olszewski, AJ, Barth, P, Mikala, G, Chim, CS & Vesole, DH 2020, 'Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients', Leukemia and Lymphoma, vol. 61, no. 8, pp. 1885-1893. https://doi.org/10.1080/10428194.2020.1749605

@article{9b0ff142379947c88d4bd11dda4e0e98,

title = "Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients",

abstract = "The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients–223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).",

keywords = "MAF, Translocation, myeloma, survival, t(14;16), t(14;20)",

author = "Sarah Goldman-Mazur and Artur Jurczyszyn and Castillo, {Jorge J.} and Anna Waszczuk-Gajda and Norbert Grz{\c a}{\'s}ko and Jakub Radocha and Max Bittrich and Kort{\"u}m, {Klaus Martin} and Alessandro Gozzetti and Lidia Usnarska-Zubkiewicz and Valls, {Julio D.} and Jayabalan, {David S.} and Ruben Niesvizky and Julia Kelman and Daniel Coriu and Laura Rosi{\~n}ol and {\L}ukasz Szukalski and Veronica Gonz{\'a}lez-Calle and Mateos, {Mar{\'i}a Victoria} and Krzysztof Jamroziak and Iwona Hus and Irit Avivi and Yael Cohen and Piotr Mazur and Anna Suska and Aimee Chappell and Deepu Madduri and Saurabh Chhabra and Ariel Kleman and Parameswaran Hari and Michel Delforge and Pawe{\l} Robak and Massimo Gentile and Izabela Koz{\l}owska and Goldberg, {Stuart L.} and Jacek Czepiel and Monika D{\l}ugosz-Danecka and Rebecca Silbermann and Olszewski, {Adam J.} and Peter Barth and Gabor Mikala and Chim, {Chor S.} and Vesole, {David H.}",

note = "Publisher Copyright: {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

month = jul,

day = "2",

doi = "10.1080/10428194.2020.1749605",

language = "English (US)",

volume = "61",

pages = "1885--1893",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

AU - Goldman-Mazur, Sarah

AU - Jurczyszyn, Artur

AU - Castillo, Jorge J.

AU - Waszczuk-Gajda, Anna

AU - Grząśko, Norbert

AU - Radocha, Jakub

AU - Bittrich, Max

AU - Kortüm, Klaus Martin

AU - Gozzetti, Alessandro

AU - Usnarska-Zubkiewicz, Lidia

AU - Valls, Julio D.

AU - Jayabalan, David S.

AU - Niesvizky, Ruben

AU - Kelman, Julia

AU - Coriu, Daniel

AU - Rosiñol, Laura

AU - Szukalski, Łukasz

AU - González-Calle, Veronica

AU - Mateos, María Victoria

AU - Jamroziak, Krzysztof

AU - Hus, Iwona

AU - Avivi, Irit

AU - Cohen, Yael

AU - Mazur, Piotr

AU - Suska, Anna

AU - Chappell, Aimee

AU - Madduri, Deepu

AU - Chhabra, Saurabh

AU - Kleman, Ariel

AU - Hari, Parameswaran

AU - Delforge, Michel

AU - Robak, Paweł

AU - Gentile, Massimo

AU - Kozłowska, Izabela

AU - Goldberg, Stuart L.

AU - Czepiel, Jacek

AU - Długosz-Danecka, Monika

AU - Silbermann, Rebecca

AU - Olszewski, Adam J.

AU - Barth, Peter

AU - Mikala, Gabor

AU - Chim, Chor S.

AU - Vesole, David H.

PY - 2020/7/2

Y1 - 2020/7/2

N2 - The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients–223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).

AB - The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients–223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24–3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).

KW - MAF

KW - Translocation

KW - myeloma

KW - survival

KW - t(14;16)

KW - t(14;20)

UR - http://www.scopus.com/inward/record.url?scp=85083656922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083656922&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1749605

DO - 10.1080/10428194.2020.1749605

M3 - Article

C2 - 32306794

AN - SCOPUS:85083656922

SN - 1042-8194

VL - 61

SP - 1885

EP - 1893

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 8

ER -

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this